Effect of (+/-)- @entity1855 and XXXX on stress- and chemically-induced @entity2275 in @entity35 .

@entity2515 @entity1855 @entity1066 @entity2514 @entity2041 @entity35 @entity3352 @entity1068 @entity2275
The influence of (+/-)- @entity1855 and @entity2514 on stress- and various chemically-induced @entity2275 in @entity35 together with their influence on various biochemical parameters which affect the development of the induced @entity1066 was examined. Pretreatment of @entity35 with (+/-)- @entity1855 (4-16 mg kg-1 orally) significantly decreased cold-stress-induced @entity2275 and enhanced @entity1068 -induced @entity1066 . It did not affect @entity3352 - (30 mg kg-1 orally) or @entity2515 - (5 mg kg-1 i.p.) induced @entity1066 . Pretreatment of the animals with @entity2514 (1-10 mg kg-1 orally) significantly enhanced @entity1068 -, @entity2515 - and cold-stress-induced @entity1066 . It did not affect @entity3352 -induced @entity1066 . Pretreatment of the animals with @entity1855 increased gastric mucus secretion, inhibited gastric acid secretion, decreased @entity2041 content and enhanced gastric lipid peroxidation whereas pretreatment of the animals with @entity2514 significantly decreased gastric mucus secretion. @entity2514 did not affect gastric acid secretion, @entity2041 or gastric lipid peroxidation. The results of this study suggest that @entity1855 -induced protection against stress-induced @entity1066 may be due to its ability to suppress gastric acid secretion and to increase gastric mucus secretion. Its enhancement of @entity1068 -induced @entity1066 may be due to its ability to increase lipid peroxidation. The @entity2514 -induced enhancement of the experimentally-induced @entity1066 may be due to its ability to suppress gastric mucus secretion.
